Scarica l'app Stockscreener
51.89
5.67%
2.785
Spruce Biosciences Inc Borsa (SPRB) Ultime notizie
SPRB Initiated Coverage by Jones Trading -- Rating Set to Buy - GuruFocus
Jones Trading initiates Spruce Biosciences stock with buy rating on therapy potential By Investing.com - Investing.com Australia
Spruce Biosciences (SPRB) Reports Promising Long-Term Results fo - GuruFocus
Jones Trading initiates Spruce Biosciences stock with buy rating on therapy potential - Investing.com UK
Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B Presented at the 18th International MPS Symposium - Investing News Network
Spruce says long-term TA-ERT data presented at MPS Symposium - TipRanks
Spruce Biosciences stock rises on MPS IIIB data, analyst initiation - Investing.com
Spruce Biosciences stock rises on MPS IIIB data, analyst initiation By Investing.com - Investing.com Canada
Spruce Biosciences (SPRB) Reports Promising Long-Term Results for Enzyme Therapy - GuruFocus
Spruce presents six-year data on MPS IIIB therapy candidate By Investing.com - Investing.com South Africa
Spruce presents six-year data on MPS IIIB therapy candidate - Investing.com
Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium - Business Wire
SPRB News | SPRUCE BIOSCIENCES INC (NASDAQ:SPRB) - ChartMill
Spruce Biosciences (SPRB) Edges Lower Amid Consolidation PhaseChart Pattern Alerts - newsline.com
SPRB Technical Analysis | Trend, Signals & Chart Patterns | SPRUCE BIOSCIENCES INC (NASDAQ:SPRB) - ChartMill
Spire Global, Inc. (SPIR) Is Up 7.94% in One Week: What You Should Know - Yahoo Finance
H.C. Wainwright Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Cuts Target Price to $150 - Moomoo
SPRB Maintains Buy Rating by HC Wainwright & Co. -- Price Target Lowered to $150 - GuruFocus
Spruce Biosciences price target lowered to $150 from $200 at H.C. Wainwright - TipRanks
Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium - BioSpace
Spruce Biosciences Announces Data Presentation At The 18Th International MPS Symposium - TradingView
Spruce Biosciences to Participate in Upcoming Conferences in June 2026 - BioSpace
Spruce Biosciences to Participate in Upcoming Conferences in June - Investing News Network
Spruce Biosciences Stockholders Approve Directors and Annual Say-on-Pay - The Globe and Mail
Oppenheimer Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Cuts Target Price to $230 - Moomoo
Oppenheimer lowers Spruce Biosciences stock price target to $230 By Investing.com - Investing.com South Africa
Oppenheimer lowers Spruce Biosciences stock price target to $230 - Investing.com
Spruce Biosciences (SPRB) director granted 1,700 stock options at 52.70 - Stock Titan
Director Camilla V. Simpson awarded 1,700 SPRB options at $52.70 strike - Stock Titan
Spruce Biosciences (SPRB) chair receives grant of 1,700 stock options - Stock Titan
Spruce Biosciences (NASDAQ: SPRB) grants director 1,700 options - Stock Titan
Spruce Biosciences (SPRB) grants director Keli Walbert 1,700 options - Stock Titan
Spruce Biosciences (SPRB) 2026 annual meeting and say-on-pay votes - Stock Titan
Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy - Yahoo Finance
Spruce Biosciences Inc (SPRB) Stock Price, Quote, News & History - Benzinga
SPRB: Directors elected, all proposals approved, and strategic plans funded for regulatory milestones - TradingView
SPRB: All proposals passed, with updates on financing, manufacturing, and regulatory milestones shared - TradingView
Wall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to Trade - MSN
Is Spruce Biosciences (SPRB) Overvalued After Q1 2026 EPS Beat? - GuruFocus
Citadel entities, Kenneth Griffin hold ~5.1% of Spruce Biosciences (SPRB) - Stock Titan
Alyeska Group (SPRB) discloses 61,670-share position, 4.49% of float - Stock Titan
Leerink Partners Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Cuts Target Price to $120 - Moomoo
Squadron entities report 12,200 SPRB shares (0.9%) — SPRB - Stock Titan
Wellington Group discloses 48,796 shared dispositive shares in Spruce Biosciences (NASDAQ: SPRB) - Stock Titan
SPRB Maintains by Citizens -- Price Target Lowered to $150 - GuruFocus
Spruce Biosciences 1Q Research and Development Expenses $7.6M >SPRB - Moomoo
Spruce Biosciences, Inc. Stock 12‑Month Price Target Cut to $178.6, Implies 210% Upside - TradingView
Spruce Biosciences Is Maintained at Market Outperform by Citizens - Moomoo
Spruce Biosciences price target lowered to $150 from $170 at Citizens - TipRanks
Citizens lowers Spruce Biosciences stock price target on model update By Investing.com - Investing.com Nigeria
Citizens lowers Spruce Biosciences stock price target on model update - Investing.com
1.04%
0.76%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):